MX371033B - Productos farmacéuticos mejorados de péptido para resistencia a la insulina. - Google Patents

Productos farmacéuticos mejorados de péptido para resistencia a la insulina.

Info

Publication number
MX371033B
MX371033B MX2016015594A MX2016015594A MX371033B MX 371033 B MX371033 B MX 371033B MX 2016015594 A MX2016015594 A MX 2016015594A MX 2016015594 A MX2016015594 A MX 2016015594A MX 371033 B MX371033 B MX 371033B
Authority
MX
Mexico
Prior art keywords
insulin resistance
improved peptide
peptide pharmaceuticals
pharmaceuticals
modified peptides
Prior art date
Application number
MX2016015594A
Other languages
English (en)
Other versions
MX2016015594A (es
Inventor
J Nestor John
Original Assignee
Mederis Diabetes Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mederis Diabetes Llc filed Critical Mederis Diabetes Llc
Publication of MX2016015594A publication Critical patent/MX2016015594A/es
Publication of MX371033B publication Critical patent/MX371033B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

La presente invención se refiere a métodos de síntesis y usos terapéuticos de péptidos y/o proteínas modificados covalentemente. Los péptidos y/o proteínas modificados covalentemente permiten propiedades farmacéuticas mejoradas de productos terapéuticos a base de péptido y/o proteína.
MX2016015594A 2014-05-28 2015-05-28 Productos farmacéuticos mejorados de péptido para resistencia a la insulina. MX371033B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004156P 2014-05-28 2014-05-28
PCT/US2015/033042 WO2015184177A1 (en) 2014-05-28 2015-05-28 Improved peptide pharmaceuticals for insulin resistance

Publications (2)

Publication Number Publication Date
MX2016015594A MX2016015594A (es) 2017-03-23
MX371033B true MX371033B (es) 2020-01-13

Family

ID=54699825

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015594A MX371033B (es) 2014-05-28 2015-05-28 Productos farmacéuticos mejorados de péptido para resistencia a la insulina.

Country Status (14)

Country Link
US (3) US9856306B2 (es)
EP (1) EP3155017B1 (es)
JP (3) JP6697807B2 (es)
KR (2) KR20230084337A (es)
CN (5) CN106661097A (es)
AU (3) AU2015266854B2 (es)
BR (1) BR112016027595B1 (es)
CA (1) CA2949701C (es)
DK (1) DK3155017T3 (es)
FI (1) FI3155017T3 (es)
IL (3) IL249044B (es)
MX (1) MX371033B (es)
NZ (2) NZ726623A (es)
WO (1) WO2015184177A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108892709A (zh) 2011-05-18 2018-11-27 欧莫德里斯制药公司 改良的肽药物
KR102011924B1 (ko) 2011-05-18 2019-08-21 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
EP3444281B1 (en) * 2012-11-20 2021-11-03 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
MX360816B (es) 2012-11-20 2018-11-15 Mederis Diabetes Llc Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina.
MX371033B (es) 2014-05-28 2020-01-13 Mederis Diabetes Llc Productos farmacéuticos mejorados de péptido para resistencia a la insulina.
WO2019018350A1 (en) 2017-07-17 2019-01-24 Keith Roizman TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
EP3735295A1 (en) * 2018-01-03 2020-11-11 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders
WO2021168386A1 (en) * 2020-02-21 2021-08-26 Spitfire Pharma Llc Glp-1r and gcgr agonists, formulations, and methods of use
IL303512A (en) * 2020-12-07 2023-08-01 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose or body weight using balanced GLP-1R and GCGR agonists
CN117202924A (zh) * 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
CN113461747B (zh) * 2021-07-12 2023-02-03 吉林化工学院 刺玫果中2个具有降血糖活性的化合物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
JPH1160598A (ja) 1997-08-15 1999-03-02 Asahi Glass Co Ltd オピオイド様ペプチド
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
RU2181729C1 (ru) 2000-09-20 2002-04-27 Калюжин Олег Витальевич Производные мурамовой кислоты
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6864069B2 (en) * 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
NZ532027A (en) 2001-10-10 2008-09-26 Neose Technologies Inc Remodeling and glycoconjugation of peptides
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20110257096A1 (en) 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
ITRM20040607A1 (it) 2004-12-15 2005-03-15 Biogen S R L Analoghi della dermorfina ad attivita' analgesica.
US7776819B2 (en) 2005-03-03 2010-08-17 The Board Of Trustees Of The University Of Illinois Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization
WO2006121860A2 (en) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2007002465A2 (en) 2005-06-23 2007-01-04 Rapid Pharmaceuticals, Llc Stabilizing alkylglycoside compositions and methods thereof
ES2397289T3 (es) 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
WO2007060692A2 (en) 2005-11-24 2007-05-31 Brain N' Beyond Biotech Pvt. Ltd. Compositions for increasing bioavailability of peptides or proteins and method thereof
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008052043A2 (en) 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
KR20090119876A (ko) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
PA8830501A1 (es) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
KR101453037B1 (ko) 2011-03-23 2014-10-21 주식회사 엘지화학 전극조립체 및 이의 제조방법
KR102011924B1 (ko) * 2011-05-18 2019-08-21 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
CN108892709A (zh) * 2011-05-18 2018-11-27 欧莫德里斯制药公司 改良的肽药物
EP3444281B1 (en) 2012-11-20 2021-11-03 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
MX360816B (es) 2012-11-20 2018-11-15 Mederis Diabetes Llc Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina.
WO2014170496A1 (en) * 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX371033B (es) 2014-05-28 2020-01-13 Mederis Diabetes Llc Productos farmacéuticos mejorados de péptido para resistencia a la insulina.
BR112017008160A8 (pt) * 2014-10-24 2023-04-11 Merck Sharp & Dohme Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição
EP3735295A1 (en) * 2018-01-03 2020-11-11 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders

Also Published As

Publication number Publication date
JP2020143066A (ja) 2020-09-10
US20200277351A1 (en) 2020-09-03
JP2017519739A (ja) 2017-07-20
CN117180445A (zh) 2023-12-08
AU2020203609A1 (en) 2020-06-25
AU2023200659A1 (en) 2023-05-11
AU2015266854A2 (en) 2017-03-09
AU2015266854B2 (en) 2020-03-26
KR20230084337A (ko) 2023-06-12
EP3155017B1 (en) 2024-01-10
NZ726623A (en) 2020-02-28
IL275526A (en) 2020-08-31
CN117582516A (zh) 2024-02-23
AU2020203609B2 (en) 2022-11-17
US20180194826A1 (en) 2018-07-12
CA2949701C (en) 2023-12-12
CN106661097A (zh) 2017-05-10
JP6697807B2 (ja) 2020-05-27
KR20170010412A (ko) 2017-01-31
CA2949701A1 (en) 2015-12-03
FI3155017T3 (fi) 2024-04-17
US9856306B2 (en) 2018-01-02
AU2015266854A1 (en) 2016-12-15
CN109865142A (zh) 2019-06-11
BR112016027595A2 (pt) 2017-08-15
CN113264994A (zh) 2021-08-17
DK3155017T3 (da) 2024-04-15
IL275526B (en) 2021-08-31
IL249044B (en) 2020-07-30
US10577405B2 (en) 2020-03-03
WO2015184177A1 (en) 2015-12-03
EP3155017A4 (en) 2019-03-27
IL285613A (en) 2021-09-30
JP2022172128A (ja) 2022-11-15
IL249044A0 (en) 2017-01-31
EP3155017A1 (en) 2017-04-19
KR102542164B1 (ko) 2023-06-12
MX2016015594A (es) 2017-03-23
US20170096468A1 (en) 2017-04-06
NZ757113A (en) 2022-08-26
BR112016027595B1 (pt) 2023-12-26
BR112016027595A8 (pt) 2021-07-20

Similar Documents

Publication Publication Date Title
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
MX2016015594A (es) Productos farmaceuticos mejorados de peptido para resistencia a la insulina.
MX344219B (es) Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
WO2012158964A3 (en) Improved peptide pharmaceuticals for osteoporosis
IL251462A0 (en) Pharmaceutical formulations for oral administration of peptide or protein drugs
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
BR112018072783A2 (pt) proteínas de fusão elp para liberação controlada e retardada
EP3200812A4 (en) Novel 4 7 peptide monomer and dimer antagonists
EP3490538A4 (en) PARTICLES FOR THE ADMINISTRATION OF PROTEINS AND PEPTIDES
EP3538542A4 (en) CYCLIC PEPTIDIC MULTIMERS TARGETING ALPHA4BETA7 INTEGRIN
HK1247831A1 (zh) 蛋白質或肽傳遞用的可溶性微針
IL252902A0 (en) Amino acid and peptide conjugates and their uses
EP3568468A4 (en) RECOMBINATION PRODUCTS TARGETING PEPTIDE HISTONE H3 / MHC COMPLEXES AND THEIR USES
ZA202004658B (en) Pharmaceutical composition comprising an apl type peptide
HK1248729A1 (zh) 細胞毒性hexim1肽和其用途
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
IL266632B (en) A molecule that accelerates the breakdown of the ras protein and a pharmaceutical preparation
EP3186272A4 (en) Functionalized beta-sheet peptide stabilized membrane proteins, constructs comprising same, and methods of forming and using same
EP3419962A4 (en) AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION METHOD
EP3491009A4 (en) PROTEIN EXPRESSION AMPLIFIER SEQUENCES AND USE THEREOF
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
AU2017305946A8 (en) C1q and HMGB1 fusion proteins and uses thereof
EP3345003A4 (en) IDENTIFICATION OF PROTEINS IN THE ABSENCE OF PEPTIDE IDENTIFICATION
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
EP3474826A4 (en) PHARMACEUTICAL PREPARATION FOR ADMINISTRATION OF PEPTIDES AND PROTEINS

Legal Events

Date Code Title Description
FG Grant or registration